Tenon MedicalTNON
TNON
About: Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants, and 3) SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
Employees: 21
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
235% more capital invested
Capital invested by funds: $48.5K [Q3] → $163K (+$114K) [Q4]
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
50% more funds holding
Funds holding: 8 [Q3] → 12 (+4) [Q4]
0.74% more ownership
Funds ownership: 2.02% [Q3] → 2.76% (+0.74%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for TNON.
Financial journalist opinion
Based on 3 articles about TNON published over the past 30 days
Neutral
Accesswire
2 days ago
Tenon Medical, Inc. Announces a Warrant Inducement Transaction for $3.0 Million in Gross Proceeds
LOS GATOS, CA / ACCESS Newswire / March 11, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of the Company for the immediate exercise of Series A Warrants to purchase up to 1,222,850 shares of common stock (the "Series A Warrants") and Series B Warrants to purchase up to 1,222,850 shares of common stock (the "Series B Warrants", and together with the Series A Warrants the "Existing Warrants") at a reduced exercise price of $1.25 for gross cash proceeds of approximately $3.0 million, before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
Neutral
Accesswire
3 days ago
Tenon Medical(R) Receives Approval for Notice of Allowance from the European Patent Office
LOS GATOS, CA / ACCESS Newswire / March 10, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, announced today the Company has been notified by the European patent office that two additional patents directed to the novel Catamaran SI Joint Fixation Device have been approved for grant of a European patent within the European Community. "The Tenon Medical team is pleased to receive recognition from the European Community for our novel Catamaran® SI joint prostheses," commented Richard Ginn, Co-Founder and Chief Technology Officer of Tenon Medical.
Neutral
Accesswire
6 days ago
Tenon Medical, Inc. Announces Timing of Fourth Quarter and Full Year 2024 Financial Results
LOS GATOS, CA / ACCESS Newswire / March 7, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced plans to release financial results for the fourth quarter and full year 2024 ended December 31, 2024 after market close on Thursday, March 20, 2025. The Company will also hold a conference call the same day at 4:30 p.m.
Neutral
Accesswire
2 months ago
Tenon Medical(R) to Host Meetings During the 2025 J.P. Morgan Healthcare Conference in San Francisco
LOS GATOS, CA / ACCESSWIRE / January 9, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced that Chief Financial Officer Kevin Williamson will host one-on-one investor meetings in San Francisco, CA during the week of January 13th in accordance with the 43rd Annual J.P. Morgan Healthcare Conference.
Neutral
Seeking Alpha
3 months ago
Tenon Medical, Inc. (TNON) Q3 2024 Earnings Call Transcript
Tenon Medical, Inc. (NASDAQ:TNON ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Steven Foster - President & CEO Kevin Williamson - CFO Conference Call Participants Anthony Vendetti - Maxim Group Operator Greetings, and welcome to the Tenon Medical Third Quarter 2024 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded.
Neutral
Accesswire
3 months ago
Tenon Medical Reports Third Quarter 2024 Financial Results
~ 3Q Revenue of $0.9 Million, Consistent with Prior Quarter; Year to Date Revenue of $2.5 Million, Growth of 18.3% Compared to Prior Year ~ ~ Published Interim Analysis from MAINSAIL™ Study; Post-Market Study Supports the Safety and Efficacy of the Catamaran SI Joint Fusion System® Including Radiographic Proof of Fusion ~ ~ Initial Clinical Procedures Completed with New Catamaran SE Platform ~ ~ Granted Issuance of Three U.S. Patents ~ ~ Received Net Proceeds of ~$9.6 Million from Equity Financing Transactions ~ LOS GATOS, CA / ACCESSWIRE / November 13, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Subsequent Highlights Revenue of $0.9 Million in the third quarter of 2024, a 1.6% decrease over the second quarter of 2024.
Neutral
Accesswire
4 months ago
Tenon Medical Announces Initial Clinical Cases Successfully Completed with Company's New Catamaran(R) SE SI Joint Fusion System
~ Procedures Completed in Various Spine & Pain Centers of Excellence Throughout the Country Including in Idaho, Pennsylvania, Minnesota, Arizona and Utah ~ ~ Feedback From Initial Physician Users to Support Broader Market Introduction~ LOS GATOS, CA / ACCESSWIRE / October 30, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced completion of the initial clinical cases utilizing the Company's new Catamaran SE SI Joint Fixation Device. The new implant offers a 30% reduction in implant width as compared to the original Catamaran Fixation Device, providing physicians with options for smaller SI joint anatomy or revising previously treated SI joints with failed alternative SI joint implants where space is limited.
Neutral
Accesswire
4 months ago
Tenon Medical, Inc. Announces Timing of Third Quarter 2024 Financial Results
LOS GATOS, CA / ACCESSWIRE / October 30, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced plans to release financial results for the third quarter 2024 ended September 30, 2024 after market close on Wednesday, November 13, 2024. The Company will also hold a conference call the same day at 4:30 p.m.
Neutral
Accesswire
4 months ago
Tenon Medical(R) Regains Full Compliance with Nasdaq Continued Listing Requirements
LOS GATOS, CA / ACCESSWIRE / October 28, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced that it is in compliance with all relevant Nasdaq continued listing Rules. The Company had previously reported non compliance with Nasdaq Rules 5605(b)(1), 5605(c)(2) and 5605(d)(2), with respect to the number of independent directors on its board of directors and certain board committees; Nasdaq Rule 5550(a)(2), with respect to its minimum bid price; Nasdaq Rule 5550(a)(4), with respect to number of shares in its public float; and Nasdaq Rule 5550(b), with respect to its stockholders' equity.
Neutral
Accesswire
4 months ago
Tenon Medical(R) Announces Issuance of Three U.S. Patents
Further Solidifies International Patent Portfolio and Underscores the Company's Commitment to Innovation of SI Joint Stabilization Systems and Methods LOS GATOS, CA / ACCESSWIRE / October 17, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced the issuance of U.S. Patent Nos. 12,115,075, 12,115,076 and 12,115,077.
Charts implemented using Lightweight Charts™